Drug discovery and development is a lengthy and expensive process. Although no one, simple, single solution can significantly accelerate this process, steps can be taken to avoid unnecessary delays. Using the development of antiviral therapies as a model, we describe options for acceleration that cover target selection, assay development and high-throughput screening, hit confirmation, lead identification and development, animal model evaluations, toxicity studies, regulatory issues, and the general drug discovery and development infrastructure. Together, these steps could result in accelerated timelines for bringing antiviral therapies to market so they can treat emerging infections and reduce human suffering.
INTRODUCTION TO THE DRUG DISCOVERY AND DEVELOPMENT PROCESS
The path from identifying a new molecular entity to gaining regulatory approval is often long and expensive. Estimates generally range from 10 to 15 years, with timelines sometimes even longer, driven by the increased complexity of drug development and tightening regulatory standards. This protracted timeline has numerous disadvantages, including the delay in the development of new medicines with lifesaving potential and the capital required to fund each phase of the development process. Although there are no simple solutions to shorten this timeline, approaches at several levels can make the process more efficient and, when taken together, could make a significant difference in the way new therapies are discovered and developed. Herein we highlight opportunities at several steps in the drug discovery and development pipeline that would improve the quality of the science and the pace of regulatory approval. A variety of stakeholders are involved at different junctures of drug development, and thus, interdisciplinary collaborative approaches are required to result in meaningful improvements.
A generalized description of the pipeline includes the following steps, although individual programs may differ in their approach to lead molecule identification [e.g., high-throughput screening (HTS) versus structure-based rational design, among other approaches]:
1. Target identification and validation 2. Assay development and HTS 3. Hit confirmation and profiling in secondary and tertiary assays 4. Lead identification and optimization using rational drug design; medicinal chemistry; and absorption, distribution, metabolism, and elimination parameters 5. Nonclinical safety and efficacy studies 6. Scale-up and production 7. Clinical trials 8. Drug regulatory approval
We use the development of antiviral therapies for emerging and reemerging viruses as a model to illustrate how, at each step of the development pathway, gains can be achieved. The therapeutic area of antiviral drug development is particularly important for accelerated development, considering the clear unmet medical need to treat emerging infections. Most of these diseases have plagued the developing world, reducing financial incentives for pharmaceutical companies to invest in programs aimed at treating diseases caused by West Nile virus (WNV) (1-4); dengue; chikungunya (5-7); coronaviruses associated with Middle East respiratory syndrome (MERS) (8, 9) and severe acute respiratory syndrome (SARS) (10-12); Ebola (13-15); and, most recently, enterovirus D68 (16) and Zika virus (17) (18) (19) (20) . Currently, no approved vaccines or treatments exist for any of these infections, with the exception of a commercial dengue vaccine approved recently in Mexico, Brazil, and the Philippines (21) . With respect to therapeutic small molecules, most currently available antivirals target human immunodeficiency virus (HIV), hepatitis B and C viruses (HBV and HCV), herpesviruses, and influenza viruses.
TARGET IDENTIFICATION AND VALIDATION
The first step in most drug discovery programs is to identify the structure and function of the molecule that the hypothetical drug is meant to act on (i.e., the therapeutic target). The choice of the target is informed by basic biology and virology and by identifying critical steps in a viral life cycle and the genes and proteins that are essential for replication. These can be derived from either the virus or the host cell, with advantages and disadvantages for either approach. Targeting viral components will likely result in drugs with fewer side effects and greater specificity because of the higher likelihood that the drug would inhibit only viral replication, without affecting host cell processes. A challenge of this approach is that the target may not be conserved across related viruses, even within serotypes or genotypes of the same virus, limiting the drug's spectrum of activity, as seen recently with many developed HCV antivirals (22) . Another drawback of manipulating viral targets is the high genetic adaptability of the virus and the potential for the emergence of drugresistant mutants. This problem has been observed for oseltamivir in the treatment of seasonal H1N1 influenza, potentially limiting the drug's usefulness over time (23) .
The potential drawbacks of viral targets, but more often the lack of lead molecules with virusspecific mechanisms, have prompted the scientific community to explore targets derived from the human host, on which the virus depends for its replication. The hypothesis is that multiple viruses highjack the host cell's machinery in similar ways; thus, interference with these targets would inhibit all viruses dependent on that particular host function. The primary concern of this strategy is that the cellular processes involved in viral replication are often essential for normal cellular physiology, resulting in side effects when these processes are manipulated pharmacologically (24) . Consequently, few small-molecule agents for a host target have ever been used clinically for the treatment of viral infections. Examples include hydroxyurea, an inhibitor of host ribonucleotide reductase used in the early days of HIV therapy (25) , and imiquimod, a Toll-like-receptor 7 agonist for the topical treatment of human papillomavirus (26) . However, emerging viral infections are often acute, and shorter treatment courses may suffice, potentially limiting the issue of adverse effects resulting from host target inhibition.
In contrast, potent and selective small-molecule inhibitors of viral targets have been developed and received regulatory approval for the treatment of many viral infections. Among those, nucleoside and nucleotide analogues have been used successfully as antivirals against herpesviruses (27) , HIV (28), HBV (29) , and HCV (30) . To avoid adverse effects, active nucleoside triphosphate metabolites should selectively inhibit the viral DNA or RNA polymerases but not the host polymerases (31) . Multiple nucleoside and nucleotide antivirals with broad-spectrum antiviral activity have been identified and developed. Among those, acyclic nucleoside phosphonates are probably the most relevant example (32) . Viral proteases represent additional successful antiviral targets, as demonstrated primarily in the treatment of HIV (33) and HCV (34) . In contrast to nucleoside inhibitors of viral polymerases, protease inhibitors tend to be much more selective for one virus family.
Examples of both viral and host target strategies for emerging, reemerging, and neglected viral infections are in the pipeline. The characteristics of a particular virus family may determine which strategy will yield the best result; for example, flaviviruses such as WNV and dengue have compact genomes and interact with many host cell structures and components (35, 36) . Because many of these structures and components are shared among the flavivirus family, developing a pan-flavivirus host target inhibitor is a possibility. Host targets with active antiviral ligands include inhibitors of host cell nucleoside biosynthesis, host cell lipid biosynthesis, alpha-glucosidase, glycolysis, kinases, and nucleotide synthesis pathways (37) .
Regardless of the target, the antiviral spectrum of any promising compound that has demonstrable activity against one virus or family of viruses must be characterized thoroughly, as a broadspectrum agent would ultimately be a desirable outcome. For example, a prodrug of the novel nucleoside GS-5734 evolved from a chemistry program in which the spectrum and efficacy of 1 -substituted C-nucleosides were evaluated, demonstrating that a cyano substitution exhibited the broadest spectrum of activity, compared to methyl, vinyl, or ethynyl substituents (38) . The original efforts were aimed at discovering leads directed against respiratory viruses. However, expanded antiviral testing demonstrated efficacy against HCV, yellow fever, dengue, WNV, influenza A, www.annualreviews.org • Accelerating Drug Developmentparainfluenza 3, respiratory syncytial virus (RSV), and SARS-coronavirus (38) . After further optimization of the prodrug moiety for potency and pharmacokinetics, the resulting molecule, GS-5734, has proved to exhibit potent antiviral activity across multiple filoviruses, including Ebola virus, as well as other RNA viruses such as RSV, MERS-coronavirus, and, to some extent, Junin and Lassa fever viruses (39) .
Importantly, most of the new knowledge about viral replication, pathogenesis, and epidemiology emanates from basic academic research. Traditionally, academic environments have not been conducive to drug discovery and development activities, in part owing to a lack of expertise, infrastructure, and incentives (40) . A first logical step to improve the speed of the drug discovery process is to form partnerships or consortia that merge academic virology knowledge with the drug discovery and development expertise in the biotechnology or pharmaceutical industry (41) . A few such examples are active in the antiviral domain; one is the Antiviral Drug Discovery and Development Center, or AD3C, funded by the Centers of Excellence for Translational Research program from the National Institute of Allergy and Infectious Diseases at the US National Institutes of Health (NIH). This consortium brings together basic virologists in US academia with experts in HTS, medicinal chemistry, and drug development at Southern Research, a nonprofit research institute, and Gilead Sciences, a pharmaceutical company (42) . Another slightly different example is Drug Innovation Ventures at Emory, LLC (DRIVE), a nonprofit organization at Emory University whose leaders have prior pharmaceutical industry experience to provide the infrastructure and management while relying on the basic academic virology research (43) .
ASSAY DEVELOPMENT AND HIGH-THROUGHPUT SCREENING
The next step in the drug discovery process is to identify compounds that engage and alter the function of the selected target to serve as a starting point for medicinal chemistry efforts. One approach is to conduct HTS in microtiter plates (typically 384-or 1,536-well format) using an assay that can measure the antiviral effects of thousands (or hundreds of thousands) of compounds rapidly and easily.
Such an assay can be set up in multiple ways, and depending on the assay protocol and format, a wide or more narrow net can be cast with respect to molecules that are identified as active. For example, one could set up a phenotypic assay to monitor virus replication. The assay readout could be cell viability (if the target virus causes a cytopathic effect in a host cell line), virus titer, or the level of expressed viral proteins in infected cells. Notably, any of these readouts could be affected by multiple mechanisms and not necessarily by inhibition of the target of interest. Therefore, followup assays are required to differentiate the hits according to their mode of action-for example, by identifying entry inhibitors or molecules directly inhibiting the viral polymerase. Also, assessing the ability of the hits to actually inhibit viral replication and not host cell functions is essential. Alternatively, if it were possible to produce, isolate, and purify the target and then design an assay in which compounds' target engagement could be measured directly, the mechanism of action of any identified active molecules would be intrinsically known. Nevertheless, this approach would still require evaluation in counterscreen assays to determine off-target effects. Also, if compounds require cellular metabolism, such as is required by the nucleoside or nucleotide analogues, a biochemical assay may not identify such molecules as active, resulting in false negatives.
Several parameters influence performance in HTS. The choice of assay format depends on the availability of sufficient amounts of reagents and assay adaptability to an automated HTS platform. Also, the method by which the virus stock is prepared is important for antiviral assays. Using flavivirus propagated in mosquito cells to infect a human host cell, for instance, results in good assay performance by recapitulating the natural cycle of infectivity between mosquitoes and humans. Similarly, the choice of host cell should also be considered. Activity should be evaluated in cell lines derived from the animal species in which efficacy testing will typically be performed so that confidence in target engagement in that particular species is high. As an example, GS-5734 was tested in multiple relevant human cell types, including primary macrophages and human endothelial cells, for its activity against Ebola virus, and depending on the cell line, the parent nucleoside did or did not show antiviral activity (39) . Notably, using primary human cells during the evaluation of hits is appropriate when evaluating the efficacy of compounds in the most relevant system for humans. Primary cells are usually not suitable for the actual screening campaign, owing to problems with availability, variability, and cell handling logistics; nevertheless, for secondary and tertiary assays, they are a prudent choice.
Before researchers initiate any screening campaign, the assay must be validated in a manner that assures reproducible results from day to day, plate to plate, and well to well. This reproducibility is mandatory, as the common practice is to screen all compounds initially at a single concentration in a single well to minimize cost and expand the chemical space that is covered in the screen. Alternatively, the whole library could be tested at several concentrations and/or in duplicate or even triplicate assays, but cost is usually a limiting factor to such an approach. A numerical indicator of the quality of the assay is the Z-factor (44), which should be used to confirm assay performance prior to embarking on a screening campaign. Any active molecules derived from the initial screen at a single concentration will require subsequent retesting at several concentrations to confirm their activity and to establish dose response to determine potency and efficacy. At this point, counterscreen assays are performed in parallel to exclude compounds with off-target effects from further testing.
The composition of the chemical library is critical for any HTS campaign, as it will determine the chemical space that is covered. For antivirals in particular, the type of compounds in the library that are expected to have antiviral activity will also influence the assay design. For example, nucleoside or nucleotide analogues that are included in the library and are of considerable interest will require uptake and metabolism by the cell to its active triphosphate, mandating the readout of antiviral efficacy at a time point when this process has had a chance to occur. Thus, a 24-h time point may be too short, potentially falsely identifying these compounds as inactive.
Another strategy is to use a library of compounds that have been tested in humans. If a compound is identified as active, the path to development can be shorter because the behavior of the compound in humans has already been studied. An evolution of this approach is to use existing drug scaffolds as starting points to further refine which chemotypes have attractive properties as antivirals (45) .
Medicinal chemists should evaluate the compounds identified in HTS for undesirable properties such as pan-assay interference or universally reactive groups. The molecular weight of compounds of interest should be confirmed using mass spectrometry, and a fresh supply should be used to retest activity in the original assay to confirm activity.
An alternative to HTS is to use the crystal structure of the target in conjunction with computational methods to perform in silico screening of hypothetical structures and compounds. After researchers generate lists of potential compounds, these structures will still require verification in vitro and in vivo, but this method allows investigators to probe a much larger chemical space than is possible with physical screening.
HIT CONFIRMATION IN SECONDARY AND TERTIARY ASSAYS
As alluded to above, after the initial screening campaign, the potential efficacy of any identified hits requires confirmation in secondary and tertiary assays. One or more of these assays can be www.annualreviews.org • Accelerating Drug Development 159 used to determine a structure-activity relationship (SAR) to guide the molecular optimization by medicinal chemistry to improve the potency, safety, and efficacy of the compounds. A key goal of the primary SAR assay is to quantify the potency of identified HTS hits by measuring the IC 50 , IC 90 , or both (i.e., the concentration at which 50% and 90%, respectively, of the maximal inhibition occurs). However, this potency parameter does not take into account the maximum level of inhibition. In theory, a hit may be active at very low concentrations, indicating a high potency, but with a maximum plateau of inhibition reaching only partial suppression of virus replication.
The maximum inhibition is often directly related to a mechanism by which a hit interferes with virus replication. Thus, in addition to activity determinations (for example, using the primary HTS assay), the maximum reduction of virus replication should be assessed to provide a sense of the compound efficacy (e.g., in a virus-yield or titer-reduction assay). In addition to potency and maximum efficacy, promising hits as well as their immediate analogues identified in the HTS campaign should be monitored for cytotoxicity by determining their cell cytotoxicity 50 (CC 50 ) values (i.e., concentrations reducing the viability of host cells by 50%). Many hits with narrow selectivity (i.e., low ratios of CC 50 /EC 50 ) should not be pursued further. Once desirable profiles for activity, efficacy, and selectivity are met, additional assays can be deployed to determine the mechanism of action; spectrum of inhibition across virus serotypes, families, or both; and spectrum of activity in different relevant permissive cell types. Together, these parameters are extremely helpful in identifying the most promising leads for further optimization and should not be ignored.
The exact mechanism of action of a compound does not need to be known before it is advanced into preclinical development. Contrary to popular belief, the US Food and Drug Administration (FDA) does not require that the mechanism of action be known prior to clinical testing. This information is valuable in facilitating further development processes and a path to registration, but it can be investigated on a parallel path to preclinical or clinical development so that it does not hold up the development pipeline.
LEAD IDENTIFICATION AND DEVELOPMENT USING MEDICINAL CHEMISTRY AND ABSORPTION, DISTRIBUTION, METABOLISM, AND ELIMINATION PARAMETERS
Once researchers have identified a hit that shows a desired inhibitory effect reliably, the chemical space around the structure must be explored to develop analogues for SAR determination. To accelerate the initial SAR determination, available analogues can be purchased prior to or in parallel with synthesis of new compounds. In so doing, chemists can rapidly determine the constituents of the molecule responsible for its activity. At this stage, especially if multiple chemical series are being explored, knowledge regarding the freedom to operate with respect to the existing patent landscape is essential (46) . Although niche patent applications can certainly be crafted to avoid existing intellectual property, elucidating novel molecular structures without intellectual property encumbrances smooths the development path and increases the probability of finding a development partner.
When exploring the chemical space, it is important to keep the ultimate goal of developing a safe and effective drug in mind. For this reason, several parameters need to be evaluated in addition to potency and efficacy because they will indicate the drug-like properties of the designed compounds. These include the following, among others:
Molecular weight
Target values for these parameters will differ, depending on the ultimate indication and route of administration. As an example, for WNV, owing to its central nervous system complications, a drug treating this disease will have to be able to cross the blood-brain barrier. For diseases with profound effects on the respiratory system, such as SARS and MERS, accumulation of drug in the lung will be of considerable importance. The route of drug administration, namely intravenous, intramuscular, or oral, will also vary according to the disease being treated. For example, if a drug will be given as a prophylactic in a tropical climate where refrigeration is limited, a stable oral tablet formulation will be preferred, necessitating good bioavailability and stability. For the treatment of life-threatening infections in a hospital setting, such as Ebola, a disease associated with profuse diarrhea, a parenteral route of administration might be acceptable, eliminating the need for optimization of a compound's oral bioavailability. Determining the target product profile (TPP) at the outset-namely, determining the outline of the package insert-will clarify the most important characteristics of the drug in development. The TPP should be agreed on by all stakeholders.
Crystallography can guide optimization of interactions between compounds and the binding pocket, if there is one. If crystal structures of related targets are available, such knowledge might be helpful in improving the selectivity of the compounds to be designed and synthesized.
In addition to determining microsomal stability, it is also useful to get a sense of the specific metabolic degradation of the compounds. This can be done in vitro first to identify the metabolic pathways but ultimately needs to be confirmed in an animal model and human volunteers. Indeed, the metabolites can be inactive or have either beneficial (enhanced activity) or deleterious (toxic) effects. Dominant metabolites should also be tested for antiviral activity. In these studies, researchers must consider the impact of the lead molecule or metabolites on the cytochrome P450 system that could influence metabolism and lead to potential drug-drug interactions. Such knowledge is essential before clinical application, and investigators should be made aware of these liabilities, especially if they cannot be addressed by changing the compound's molecular structure.
Prior to or in parallel with pharmacokinetic (PK) evaluation in animals, it would be prudent to test the compounds against a human receptor panel, including human ether-à-go-go-related gene (hERG). When this channel is impacted, it can lead to cardiac arrhythmias; this has been a common cause of agents failing in clinical trials.
Once compounds having a desirable profile are identified, the PK properties are determined in the animal species of choice via the route of administration that will be used to determine efficacy in both animal and human studies. If applicable, oral bioavailability should be tested. In addition, tissue distribution should be evaluated to ensure sufficient levels of unbound drug reach the site of human disease. In sum, the main question that needs to be answered is whether the compound can achieve sufficiently high concentrations for an appropriate period of time at the site of action to mediate a pharmacological effect.
Notably, many of these evaluations can be outsourced to contract research organizations (CROs). This is often faster than building the infrastructure and expertise to set up assays inhouse, especially if in-house resources are nonexistent or at capacity.
ANIMAL MODELS
Before proceeding to human studies, a reliable animal model is desirable to test the efficacy of candidate compounds. Efficacy studies in a relevant animal model may help estimate human dose,
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barriers to the emergence of resistance, and drug tolerability in the context of viral infection. However, not all viral diseases have reproducible, validated, or easily available animal models with pathology, virus tropism, and replication kinetics mimicking human infection. One of the limiting issues in the development of new therapeutics is the lack of predictive power of animal models used before testing drugs in humans, as concluded in a recent publication that applied decision theory to the drug discovery process (47) . The authors readily admit that estimating the predictive validity of models comes down to making educated guesses, but they nonetheless suggest that this mathematical framework allows for ideas that could improve the chance of development success. Experienced scientists should use their intuition about the predictive value of a model and use only the best models, even if the complexity of the model allows fewer therapeutic candidates to be tested for efficacy. The challenge of the predictability of disease models is likely less for infectious diseases than for diseases driven primarily by pathology in the human host. On the opposite end of the spectrum, some models may be too stringent and may lead to elimination of candidate molecules. Examples include frequently used mouse models developed for lethal infections, even for viruses that have relatively low mortality in humans, such as influenza (48) or dengue (49) .
Very few research laboratories worldwide have the infrastructure available for in vivo testing against highly pathogenic human infections, as these studies require tightly controlled animal facilities with biosafety containment level 3 or 4. This limits the number of lead molecules that can be tested in a timely fashion.
Species-specific drug tolerability or metabolism liabilities also may preclude facile efficacy testing in the more easily accessible animal models. For example, GS-5734 is degraded rapidly by serum esterases that are highly active in rodents but not in humans and other primates (39) .
As a consequence of these animal model challenges, a dichotomy exists between academic and commercial metrics of success: In academia, investigators are primed to publish and, therefore, perhaps more likely to emphasize studies that show any efficacy, irrespective of relevance to the human disease. In contrast, in a commercial or pharmaceutical enterprise, the ultimate goal should be to define the potential of a compound to impact the clinical course of a given disease. Even if a compound fails, whether owing to the lack of efficacy or tolerability or to undesirable PK parameters, the resulting data provide valuable information that can be directed to more productive lines of research.
The culture and reward system of commercial enterprises can mean they are not immune to the desire to show positive results. For example, a recent review analyzed the pipeline at a large pharmaceutical company and the reasons for program failure (50) . When a numbersbased approach was used to drive potential therapeutics through the pipeline, team behavior and decisions were influenced by the desire to transition candidate molecules from phase to phase in the pipeline, rather than by employees asking the killer questions that would determine the likelihood of delivering a good drug (50) . This company has since changed direction and now guides its R & D teams by a framework in which the determinants are to understand the target, patient population, target tissue, safety profile, and commercial potential (50) . It will be interesting to follow the company's R & D productivity over the next few years.
Several initiatives are now addressing the reproducibility of high-profile scientific papers, most recently by encouraging researchers to post findings at an online channel called Preclinical Reproducibility and Robustness hosted by the London-based publishers Faculty of 1000 (F1000) (51) . Although it is unclear whether this initiative will gain traction, it provides a new avenue to quickly disseminate findings of carefully controlled confirmatory experiments that are otherwise difficult to publish.
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NONCLINICAL TOXICITY STUDIES, SCALE-UP, AND MANUFACTURING
Before clinical trials in human volunteers can commence, a thorough, good laboratory practiceguided evaluation of a drug's toxicity in animals is required in at least two different species, typically a rodent and nonrodent (usually a dog). Results from these preclinical toxicology studies should do the following, at a minimum:
Establish a safe starting dose for clinical studies.
Provide information on a drug-treatment regimen that would produce the least toxicity.
Assess target organ toxicity and its reversibility.
Provide insight into biomarkers for clinical monitoring.
The choice of species is important not only for efficacy testing, as described above, but also for toxicity testing. Issues to keep in mind include the presence or absence of the target in the species, the possible presence of an irrelevant target that may confound toxicity evaluation, differences in metabolism between the animal and humans, and differences in susceptibility to infection by specific pathogens.
At this point in the development process, scale-up and manufacturing issues should be addressed. Although a discussion of these issues is outside the scope of this review, researchers should consider, for example, ease and cost of synthesis, stability or shelf life, lot-to-lot reproducibility, and capability of stockpiling to meet demand during an outbreak (e.g., pandemic H1N1 influenza); the latter point is uniquely important for antivirals.
TRIAL DESIGN AND REGULATORY ISSUES
Clinical trials for emerging infections pose unique challenges, especially for diseases with high mortality. For regulatory purposes, historically, clinical endpoints were deemed mandatory, but, as noted below, surrogate markers are increasingly being used to indicate a drug's medical relevance. Nevertheless, for diseases such as Ebola, chikungunya, and WNV encephalitis, no such biomarkers exist. For the latter two diseases in which mortality is very low, traditional, placebo-controlled studies with clinical endpoints can be envisioned. For Ebola, unique designs should be considered (52) . Such designs could (a) compare mortality in two communities, one treated and the other not (53); (b) use an adaptive, dose-escalating design (54); or (c) conduct a classic prophylactic study in exposed individuals (55) . Community ethics and standards will ultimately dictate how human health can best be improved but also how sufficient high-quality data can be collected that will inform the relevant regulating agency about therapeutic efficacy.
The FDA is in the difficult position of having to balance access to lifesaving drugs with the need for therapeutic evidence that supports the clinical use of these drugs (56) . The agency has done a remarkable job trying to accelerate the approval process. One of the first regulatory frameworks that was developed to accelerate drug approval was adopted after the onset of the AIDS epidemic and the first successful therapeutic trials of drugs targeting HIV, largely owing to pressure from AIDS activists. At that time, the FDA instituted the Fast Track designation for truly novel and potentially lifesaving therapies. A company can apply for such a designation for drugs that treat a serious or life-threatening condition and fill an unmet medical need. A drug that receives this designation typically requires more frequent meetings with the FDA, resulting in a faster resolution of items such as clinical trial design. In so doing, it also allows the company to submit portions of the New Drug Application on a rolling basis as they are completed, instead of waiting until
www.annualreviews.org • Accelerating Drug Development 163
all sections are complete and bundled. Together, these advantages can accelerate the approval process by 6-10 months, providing a substantial financial incentive. The accelerated approval process usually depends on clinical endpoints but is moving toward surrogate endpoints that have been shown or are thought to predict actual clinical benefit but that may not necessarily have been proved to do so. In infectious diseases, HIV and HCV are the only examples for which surrogate endpoints (viral load) have been utilized for approval, although surrogate endpoints are being explored for CMV infections in hematopoietic stem cell transplant recipients. However, the use of surrogate endpoints needs to be justified first by clinical validation studies that link the surrogate marker firmly with clinical outcomes. Importantly, upon accelerated approval, Phase IV studies are required by the FDA to prove that the clinical benefit indeed manifests itself upon drug treatment; should these benefits not materialize, the FDA reserves the right to withdraw the approval of marketing.
Another recent mechanism that the FDA implemented in 2012 to accelerate the approval process is the Breakthrough Therapy Designation; this designation funnels the application to the priority review list and is granted to drugs that offer significant treatment advantages over existing options for patients with serious or life-threatening conditions. In 2013, 3 such therapies were indicated as breakthrough therapies, increasing to 14 drugs in 2014 and 21 in 2015 (57, 58) .
The FDA does attend to the welfare of patients. Under unique circumstances, the FDA and the European Medicines Agency (EMA) will allow for compassionate plea release of medications that have little human data for the disease of interest. Two examples for Ebola are relevant. First, the FDA allowed for the release of ZMapp antibodies for individuals known to be infected with Ebola. In the second case, both the FDA and EMA allowed for the treatment of two infected individuals with GS-5734. Despite reports of viral clearance, actual treatment efficacy cannot be gauged from these limited exposures (59, 60) , and larger, appropriately powered clinical trials are anticipated should Ebola continue to be a threat to human health.
A beneficial mechanism that the FDA has instituted in recent years is the priority review voucher program. This program provides a voucher for priority FDA review to a company that develops a new therapy for neglected diseases, including emerging and reemerging tropical infections, but has also been extended recently to pediatric rare diseases on a trial basis. The voucher is transferrable and can be used for any therapy that any company wants to have reviewed by the FDA. This provides a lucrative incentive: For drugs expected to have large sales, shaving even mere months off of the marketing approval process could result in significant financial gains. However, a priority review voucher does not guarantee approval.
Following the anthrax release through the US mail in 2001 and the growing concern about bioterrorism, the FDA implemented the Animal Rule. The Animal Rule was designed to provide a route to licensure of medications for diseases for which human cases do not exist (61) or for which human clinical trials would be unethical, such as rabies or radiation poisoning. An example is drug discovery for the treatment of smallpox. Human smallpox has been eradicated, but pools of virus still exist that could be used for bioterrorism. Thus, the FDA agreed to use nonhuman primate models to establish safety and efficacy. Toward this end, brincidofovir is extremely active in murine pox virus models. However, it showed evidence of toxicity in a nonhuman primate model of smallpox and was ultimately not licensed for this disease for these reasons.
In all cases and indications, it is highly advisable for researchers to establish a productive, collegial working relationship with the FDA; their professionals can help guide preclinical studies and clinical development plans. In a recently published white paper, they illustrate that when drug developers hold pre-investigational new drug and end-of-Phase-I meetings with the FDA, the approval process can be accelerated by more than two years (57).
GENERAL DRUG DISCOVERY AND DEVELOPMENT INFRASTRUCTURE
As the examples provided illustrate, the discovery and development of drugs is no longer a singleinstitution endeavor. If advances are to be achieved rapidly, collaborations need to mature between pharmaceutical companies; academic investigators; US government organizations such as NIH, Centers for Disease Control and Prevention, US Army Medical Research Institute of Infectious Diseases, Department of Defense, and Biomedical Advanced Research and Development Authority; international public health agencies such as the World Health Organization, Pan American Health Organization, and the Joint United Nations Programme on HIV/AIDS; and nonprofit organizations such as the Gates Foundation and the Wellcome Trust. To streamline these publicprivate partnerships, communication is essential and must include an understanding of organizations' values, culture, and structure. It is imperative to include individuals in these collaborations who serve as liaisons and facilitators and have the trust of all stakeholders, allowing everyone to do those things that are in the common best interest. Exchange of talent and expertise is importantfor example, pharmaceutical and biotechnology companies should hire people with broad academic expertise and knowledge, and academic institutions should welcome those from industry. This will greatly facilitate the interactions and communications between these two key sectors. In addition, interdisciplinary communication should be frequent, with collaborators sharing and discussing data as they become available instead of waiting for formal quarterly reports. This provides a sense of teamwork and ownership among the involved personnel, in which everyone has a stake in getting to the correct answer as quickly as possible.
Drug developers have also suggested extending the precompetitive space to de-risk research. Although idealistic, if companies shared information on targets, especially failed targets, it would help refocus resources to explore other avenues and targets and would help other companies not waste money pursuing something that has already proved to not work. Understandably, there is skepticism about this concept, with cynical commentators predicting that companies would gladly see their competitors waste their dollars on fruitless endeavors. However, several informationsharing initiatives have shown some promise (62) , and more widespread adoption of this idea is likely in the near future.
CLOSING THOUGHTS
Unfortunately, there is no magic bullet for the long time it takes to discover and develop new therapies, including antivirals. We did not discuss the complexities of combination therapies, even though many have been successful in the treatment of HIV and HCV. Such therapies must be considered for life-threatening diseases as the drug discovery field moves forward. However, the suggestions for acceleration mentioned above, although some are deceptively simple in concept, should alleviate unnecessary delays in the progression of compounds through the pipeline. Implementing even a few of these options in a drug discovery program may speed up the development and approval of a drug by several months to potentially even years, reducing development costs and, ultimately, human suffering.
SUMMARY POINTS
1. Target identification and validation is a crucial step in which researchers strive for targets relevant to multiple pathogens. Developing seamless public-private partnerships will be
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helpful in capitalizing on the deep biology knowledge in academia with the resources in the commercial sector.
2. For assay development and high-throughput screening, defining the reproducibility of the assay before initiation of any campaign is a crucial step. Broadly diverse chemical libraries should be used for screening, including libraries of FDA-approved drugs to facilitate repurposing efforts. Liabilities of hit compounds should be identified rapidly to abandon further pursuit. The identity and activity of attractive hit compounds should be confirmed. In silico screening can be used to probe a larger chemical space.
3. Hit compounds should be confirmed in secondary and tertiary assays to determine the in vitro potency, efficacy, and selectivity early in the process of hit profiling. Also, the compounds' mechanisms of action should be determined in parallel to development, not as part of the compound progression pathway.
4. Lead compounds should be identified and developed using medicinal chemistry and guided by absorption, distribution, metabolism, and elimination parameters. Importantly, the freedom to operate should be clarified before embarking on significant chemistry efforts. A TPP should be utilized to determine target values for compounds' parameters. Initially, analogues of existing hit or lead molecules can be explored in commercially available libraries. Structural information can be explored to guide analogue design. Early on, metabolic liabilities and metabolites' efficacy and toxicity profiles should be determined. Importantly, prior to animal efficacy studies, PK parameters in vivo need to be tested. For some or all of these activities, outsourcing to CROs may be an expeditious option.
5. To test compounds in animals, the model that best reflects the human disease should be used despite potential challenges in cost, speed, compound requirements, and so on. Also, the culture of the institution in which the research is done should emphasize and reward study designs focused on truth-finding over generating positive results.
6. Nonclinical toxicity studies need to use the appropriate species for testing. For scale-up and manufacturing, a simplification of synthesis, if needed, should be initiated with the advancement of lead molecules into animal models.
7. To mitigate regulatory issues, the development team needs to engage with drug regulators early and continue seeking their feedback throughout the development process.
If justified, the team should apply for special drug development designations available from the FDA that accelerate and streamline the regulatory communication and approval process.
8. To have a supportive drug discovery and development infrastructure, it is recommended to have dedicated liaisons for interinstitutional collaborations. In these collaborations, it is best practice to share information continuously, instead of waiting for discrete progress reports. Extending the precompetitive space would benefit the industry as a whole.
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